Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Jon LeCroy

MKM Partners

Image: Jon LeCroy

Jon LeCroy joined MKM Partners in June 2011 as an analyst covering the biotechnology/specialty pharmaceuticals sector. LeCroy previously covered the same sector at Hapoalim Securities USA, Natixis Bleichroeder and Goldman Sachs. He ranked #5 in this year's Wall Street Journal "Best on the Street" poll in biotechnology. He holds a Masters in Business Administration from Boston University's Graduate School of Management, an M.D. from University of South Florida College of Medicine and a Bachelor of Science in biology from Wake Forest University.

Recent Interviews

Why M&A Flurry Has Top MKM Analyst Smiling All the Way to the Bank (8/16/12)

Sometimes bigger is better. In this exclusive interview with The Life Sciences Report, Senior Analyst and Managing Director Dr. Jon LeCroy of MKM Partners points to mergers and acquisitions that have bolstered stock prices and singles out biotech and specialty pharma companies of all sizes that could generate significant returns for investors by addressing unmet medical needs with innovative solutions.

Due to permission requirements, not all quotes are shown.